Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3 + Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.
1 . A mutated interleukin-34 (IL-34) polypeptide comprising
an amino acid sequence ranging from the asparagine residue at position 21 of SEQ ID NO: 1 to the proline residue at position 242 of SEQ ID NO: 1, wherein one or more mutations have been introduced, said one or more mutations being selected from the group consisting of:
a substitution of the serine residue at position 100 by a phenylalanine residue (S100F),
a substitution of the threonine residue at position 36 by a tyrosine residue (T36Y),
a substitution of the glutamine residue at position 131 by a phenylalanine residue (Q131F),
a substitution of the threonine residue at position 36 by a tryptophan residue (T36W),
a substitution of the threonine residue at position 36 by a phenylalanine residue (T36F),
a substitution of the histidine residue at position 56 and of the glycine residue at position 112 by a cysteine residue (H56C and G112C), and
combinations thereof.
2 . The mutated IL-34 polypeptide according to claim 1 , said polypeptide comprising
an amino acid sequence ranging from the asparagine residue at position 21 of SEQ ID NO: 1 to the proline residue at position 242 of SEQ ID NO: 1, wherein the serine residue at position 100 is substituted by a phenylalanine residue (S100F), and wherein one or more further mutations have been introduced, said one or more further mutations being selected from the group consisting of:
a substitution of the threonine residue at position 36 by a tyrosine residue (T36Y),
a substitution of the glutamine residue at position 131 by a phenylalanine residue (Q131F),
a substitution of the threonine residue at position 36 by a tryptophan residue (T36W),
a substitution of the threonine residue at position 36 by a phenylalanine residue (T36F),
a substitution of the histidine residue at position 56 and of the glycine residue at position 112 by a cysteine residue (H56C and G112C), and
combinations thereof.
3 . A fusion protein consisting of the mutated IL-34 polypeptide according to claim 1 fused to a heterologous polypeptide.
4 . The fusion protein according to claim 3 , wherein the heterologous polypeptide is an Fc region.
5 . A pharmaceutical composition comprising the mutated IL-34 polypeptide according to claim 1 , or a fusion protein consisting of said mutated IL-34 polypeptide fused to a heterologous polypeptide, with at least one pharmaceutically acceptable excipient, and optionally at least one sustained-release matrix.
6 . A mutated IL-34 polypeptide comprising
an amino acid sequence ranging from the asparagine residue at position 21 of SEQ ID NO: 1 to the proline residue at position 242 of SEQ ID NO: 1, wherein one or more mutations have been introduced, said one or more mutations being selected from the group consisting of:
a substitution of the serine residue at position 100 by an aspartic acid residue (S100D),
a substitution of the glutamine residue at position 131 by an arginine residue (Q131R), and
a combination thereof.
7 . A fusion protein consisting of the mutated IL-34 polypeptide according to claim 6 fused to a heterologous polypeptide.
8 . The fusion protein according to claim 7 , wherein the heterologous polypeptide is an Fc region.
9 . A pharmaceutical composition comprising the mutated IL-34 polypeptide according to claim 6 , or a fusion protein consisting of said mutated IL-34 polypeptide fused to a heterologous polypeptide, with at least one pharmaceutically acceptable excipient, and optionally at least one sustained-release matrix.
10 . A method of inducing immune tolerance in a subject in need thereof, comprising administering to said subject the mutated IL-34 polypeptide according to claim 1 , or a fusion protein consisting of said mutated IL-34 polypeptide fused to a heterologous polypeptide.
11 . A method of preventing or reducing transplant rejection in a subject in need thereof, comprising administering to said subject the mutated IL-34 polypeptide according to claim 1 , or a fusion protein consisting of said mutated IL-34 polypeptide fused to a heterologous polypeptide.
12 . An in vitro/ex vivo method of obtaining a population of immunosuppressive macrophages, comprising culturing a population of monocytes in a medium comprising the mutated IL-34 polypeptide according to claim 1 .